SOHO State of the Art Updates and Next Questions: BTK inhibitors combined with chemoimmunotherapy in CLL, the best of both worlds?
- 19 September 2021
- journal article
- review article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 22 (4), 205-209
- https://doi.org/10.1016/j.clml.2021.09.012
Abstract
No abstract availableThis publication has 34 references indexed in Scilit:
- Ventricular arrhythmias and sudden death in patients taking ibrutinibBlood, 2017
- First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trialThe Lancet Oncology, 2016
- Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLLBlood, 2016
- Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemiaBlood, 2016
- Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trialBlood, 2016
- Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinibBlood, 2015
- Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomesLeukemia & Lymphoma, 2014
- Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 TrialJournal of Clinical Oncology, 2012
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialThe Lancet, 2010
- Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemiaBlood, 2008